나노 바이오센서 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the nano biosensors market size is expected to grow from USD 14.58 billion in 2025 to USD 15.8 billion in 2026 and is forecast to reach USD 23.55 billion by 2031 at 8.36% CAGR over 2026-2031.

This report is Segmented by Type (Optical Sensor, Electrochemical Sensor, and More), End User Industry (Healthcare, Food and Beverage, Environmental Monitoring, and More), Technology Platform (Electrochemical, Optical, Nanomechanical, and More), Application (Medical Diagnostics, Food Safety Testing, Environmental Monitoring, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Nano Biosensors Market Trends and Insights

Rising Adoption in Point-of-Care Medical Diagnostics

Point-of-care tools are replacing centralized laboratory testing across emergency departments, rural clinics, and home-care settings because turnaround time directly influences clinical outcomes. In 2024, the United States Food and Drug Administration cleared 23 nano-enabled diagnostic platforms that deliver multiparameter results within 15 minutes using fingerstick volumes under 50 microliters. Reimbursement models such as Medicare's Hospital Readmissions Reduction Program reward hospitals that discharge patients with rapid triage data in hand, and nano-scale transducers offer femtomolar detection limits that catch sepsis biomarkers earlier than conventional immunoassays. As a result, decentralized testing is also scaling in low- and middle-income countries under the World Health Organization's ASSURED criteria, which emphasize affordability and user friendliness. The ensuing uptake supports consistent double-digit unit growth for compact handheld readers in the nano biosensors market.

Advancements in Nanomaterial Fabrication Techniques

Continuous roll-to-roll synthesis of graphene, carbon nanotubes, and quantum dots has reduced per-unit nanomaterial costs ten-fold since 2024. Inkjet-printed graphene electrodes now achieve sheet resistances below 50 Ω per square at deposition speeds above 10 m/min, enabling low-cost disposable test strips. Cadmium-free indium phosphide quantum dots comply with RoHS rules while sustaining quantum yields above 60%, a prerequisite for optical biosensors serving time-critical food-safety assays. These gains transform single-use sensor economics, bringing test prices below USD 0.50 and trimming sample-to-answer windows to under 30 minutes. ISO/TS 80004-2 issued in 2024 codifies nanomaterial terminology, reducing regulatory ambiguity and shortening product-registration cycles

Complex Manufacturing Process and Yield Variability

Multi-step fabrication that includes nanomaterial synthesis, electrode patterning, and microfluidic assembly introduces defect accumulation that suppresses yields. Pilot runs achieve 85%-92% output, yet rates drop once line speed exceeds 15 m/min because ink viscosity fluctuates and substrates distort. A 1% electrode-alignment error can cut sensor sensitivity by 12%, forcing deployment of USD 0.08-to-0.12 inline imaging per unit. Batch-to-batch material variability drives additional recalibration cycles, problematic for over-the-counter strips priced for single use. IEC 62304 traceability mandates compound documentation tasks, stretching smaller developers' resources and delaying time-to-volume ramp-ups.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Demand for Continuous Glucose Monitoring Devices
2. Integration of Biosensors with IoT Platforms
3. Stringent Regulatory Approval Pathways for Clinical Biosensors

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Optical sensor platforms in the nano biosensors market are advancing at a 9.48% CAGR, eclipsing the broader growth rate as food-safety and environmental users demand label-free, multi-analyte assays. Surface-plasmon-resonance chips and fluorescence-based transducers avoid enzyme labels that suffer cold-chain restrictions, thereby shaving logistics overhead. Electrochemical architectures still dominated 2025 with 39.72% revenue thanks to glucose and cardiac panels, yet they face interference from electroactive compounds in complex matrices, adding filtration steps that inflate bill-of-materials costs. Acoustic sensors, which read mass changes on piezoelectric crystals, are making inroads where opacity sidelines optical approaches, such as fermentation broth monitoring. Calorimetric and nanomechanical variants remain confined to research due to high instrumentation costs, though Defense Advanced Research Projects Agency funding seeks handheld prototypes by 2027, a move that could refresh product roadmaps. Overall, the shift toward optical multiplexing expands use-case breadth and underpins premium pricing, reinforcing revenue momentum for specialized suppliers.

The nano biosensors market size for optical sensors is set to expand more quickly than other types as end users value rapid, simultaneous detection that cuts total assay time. Electrochemical platforms will continue to command scale advantages in consumables, yet commoditization pressures from low-cost Asian fabs necessitate innovation in interference shielding and reagent-free chemistries. As technology choices converge on specific performance niches, vendors that tailor sensor packages to well-defined clinical or industrial problems are expected to capture disproportionate wallet share.

Environmental bodies are opening procurement budgets to tackle new contaminant classes, propelling environmental monitoring to a 8.82% CAGR, the fastest among end users. The U.S. Environmental Protection Agency's 2024 regulation putting PFAS limits at 4 ppt requires sub-ppm sensitivity that roll-to-roll nanowire sensors now achieve in under 20 minutes. Healthcare remained the largest buyer at 35.12% of 2025 spending, yet its growth moderates as CGM penetration saturates type 1 diabetic cohorts. Food and beverage processors are scaling biosensor use at loading docks and cold-chain hubs, satisfying retailer mandates for four-hour pathogen clearance windows. Defense and security agencies trial quantum-dot arrays for standoff detection of weaponized chemicals, underscoring the breadth of addressable niches in the nano biosensors industry.

Environmental adopters value low-maintenance nodes that integrate with supervisory control systems and supply granular risk analytics. These capabilities justify premium per-unit pricing despite municipal budget constraints. As benchmark contaminant lists lengthen, adoption curves are expected to remain steep, strengthening the nano biosensors market.

Complete Report Scope:

• By Type
  • Optical Sensor
  • Electrochemical Sensor
  • Acoustic Sensor
  • Other Types
• By End User Industry
  • Healthcare
  • Food And Beverage
  • Environmental Monitoring
  • Defence And Security
  • Other End Users
• By Technology Platform
  • Electrochemical
  • Optical
  • Nanomechanical
  • Calorimetric
  • Acoustic
• By Application
  • Medical Diagnostics
  • Food Safety Testing
  • Environmental Monitoring
  • Industrial Process Control
  • Others Applications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia
  • Middle East
    • Israel
    • Saudi Arabia
    • United Arab Emirates
    • Turkey
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Rest of Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific is projected to post a 9.86% CAGR to 2031, the highest regional pace in the nano biosensors market. China's 14th Five-Year Plan allocates CNY 12 billion (USD 1.7 billion) in subsidies for domestic nanomaterial and sensor capacity, while the National Medical Products Administration expedites reviews for locally developed CGM systems.India's Ayushman Bharat Digital Health Mission integrates sensor data with unified records, spurring hospital demand. Japan approved eight novel platforms in 2024 under the Society 5.0 banner, extending market presence into wellness-oriented saliva and sweat assays.

North America, which generated 34.55% of 2025 revenue, enjoys an installed base of CGM users and favorable reimbursement. Growth, however, is moderating as type 1 penetration plateaus, shifting unit volumes toward prediabetic monitoring and multi-analyte patches. European momentum depends on the In Vitro Diagnostic Regulation, which delivers a market of 450 million consumers but raises conformity assessment costs and elongates launch calendars EMA. The Middle East is investing in smart-city platforms; Dubai deployed 200 real-time water-quality nodes in 2024 under its Smart City initiative. South America and Africa remain underpenetrated owing to fragmented rules and limited cold-chain logistics, although Brazil's ANVISA eased pathways for WHO-prequalified point-of-care devices.

Collectively, regional policy support, reimbursement expansion, and manufacturing capability are reshaping market-share contours. The nano biosensors market size in Asia-Pacific is on track to surpass Europe before 2030 if current adoption trajectories persist.

1. Abbott Laboratories
2. ACON Laboratories, Inc.
3. Agilent Technologies Inc.
4. NanoScent Ltd.
5. Nanowear, Inc.
6. AerBetic LLC
7. Instant NanoBiosensors Co. Ltd.
8. LamdaGen Corporation
9. Bruker Corporation
10. Honeywell International Inc.
11. Analog Devices Inc.
12. Omron Corporation
13. Biosensors International Group Ltd.
14. Universal Biosensors Inc.
15. Medtronic plc
16. Roche Diagnostics International AG
17. Dexcom Inc.
18. STMicroelectronics N.V.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Adoption In Point-of-Care Medical Diagnostics
  • 4.2.2 Advancements In Nanomaterial Fabrication Techniques
  • 4.2.3 Growing Demand For Continuous Glucose Monitoring Devices
  • 4.2.4 Integration Of Biosensors With IoT Platforms
  • 4.2.5 Regulatory Push For Antibiotic Stewardship Using Rapid Nanobiosensor Tests
  • 4.2.6 Emergence Of Printable Flexible Substrates Enabling Disposable Food-Safety Biosensors
• 4.3 Market Restraints
  • 4.3.1 Complex Manufacturing Process and Yield Variability
  • 4.3.2 Stringent Regulatory Approval Pathways For Clinical Biosensors
  • 4.3.3 Nanomaterial Supply Chain Constraints For Rare Earth Elements
  • 4.3.4 Data Privacy Concerns In Wearable Nanobiosensor Ecosystems
• 4.4 Value-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Impact of Macroeconomic Factors on the Market
• 4.8 Porter's Five Forces Analysis
  • 4.8.1 Threat of New Entrants
  • 4.8.2 Bargaining Power of Buyers
  • 4.8.3 Bargaining Power of Suppliers
  • 4.8.4 Threat of Substitute Products
  • 4.8.5 Intensity of Competitive Rivalry
• 4.9 Industry Stakeholders Analysis
• 4.10 Patent Landscape

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Type
  • 5.1.1 Optical Sensor
  • 5.1.2 Electrochemical Sensor
  • 5.1.3 Acoustic Sensor
  • 5.1.4 Other Types
• 5.2 By End User Industry
  • 5.2.1 Healthcare
  • 5.2.2 Food And Beverage
  • 5.2.3 Environmental Monitoring
  • 5.2.4 Defence And Security
  • 5.2.5 Other End Users
• 5.3 By Technology Platform
  • 5.3.1 Electrochemical
  • 5.3.2 Optical
  • 5.3.3 Nanomechanical
  • 5.3.4 Calorimetric
  • 5.3.5 Acoustic
• 5.4 By Application
  • 5.4.1 Medical Diagnostics
  • 5.4.2 Food Safety Testing
  • 5.4.3 Environmental Monitoring
  • 5.4.4 Industrial Process Control
  • 5.4.5 Others Applications
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 United Kingdom
    • 5.5.2.2 Germany
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Rest of Asia
  • 5.5.4 Middle East
    • 5.5.4.1 Israel
    • 5.5.4.2 Saudi Arabia
    • 5.5.4.3 United Arab Emirates
    • 5.5.4.4 Turkey
    • 5.5.4.5 Rest of Middle East
  • 5.5.5 Africa
    • 5.5.5.1 South Africa
    • 5.5.5.2 Egypt
    • 5.5.5.3 Rest of Africa
  • 5.5.6 South America
    • 5.5.6.1 Brazil
    • 5.5.6.2 Argentina
    • 5.5.6.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles {(includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products And Services, And Recent Developments)}
  • 6.4.1 Abbott Laboratories
  • 6.4.2 ACON Laboratories, Inc.
  • 6.4.3 Agilent Technologies Inc.
  • 6.4.4 NanoScent Ltd.
  • 6.4.5 Nanowear, Inc.
  • 6.4.6 AerBetic LLC
  • 6.4.7 Instant NanoBiosensors Co. Ltd.
  • 6.4.8 LamdaGen Corporation
  • 6.4.9 Bruker Corporation
  • 6.4.10 Honeywell International Inc.
  • 6.4.11 Analog Devices Inc.
  • 6.4.12 Omron Corporation
  • 6.4.13 Biosensors International Group Ltd.
  • 6.4.14 Universal Biosensors Inc.
  • 6.4.15 Medtronic plc
  • 6.4.16 Roche Diagnostics International AG
  • 6.4.17 Dexcom Inc.
  • 6.4.18 STMicroelectronics N.V.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment